However, some authors have reported the therapeutic failure of ruxolitinib in treating severe fungal infections other than CMC, or early-onset inflammatory bowel disease [19, 24, 25], suggesting that larger cohort studies are recommended to support the efficacy of JAK inhibitors in STAT1-GOF patients. This evidence concerns the gene STAT1 and fungal infectious disease.